{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:47:01Z","timestamp":1771667221385,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02841","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T08:28:28Z","timestamp":1545035308000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India"],"prefix":"10.3389","volume":"9","author":[{"given":"K. K.","family":"Vidyavijayan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narayanaiah","family":"Cheedarala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemalatha","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia K.","family":"Precilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pattabiraman","family":"Sathyamurthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmapriyadarsini","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailapuri G.","family":"Murugavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumya","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikanth P.","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke Elizabeth","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ni.3158","article-title":"Antibody responses to envelope glycoproteins in HIV-1 infection","volume":"16","author":"Burton","year":"2015","journal-title":"Nat Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"310rv7","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci Transl Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1128\/JVI.01482-09","article-title":"Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables","volume":"84","author":"Doria-Rose","year":"2010","journal-title":"J Virol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"Simek","year":"2009","journal-title":"J Virol."},{"key":"B5","first-page":"101","article-title":"Human immunodeficiency virus type 2 (HIV-2)","volume":"1","author":"Kanki","year":"1999","journal-title":"AIDS Rev"},{"key":"B6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0966-842X(00)88863-0","article-title":"The epidemiology of HIV in India","volume":"3","author":"Dietrich","year":"1995","journal-title":"Trends Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3389\/fimmu.2017.00580","article-title":"Pathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 Infections","volume":"8","author":"Vidya Vijayan","year":"2017","journal-title":"Front Immunol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1126\/science.7915856","article-title":"Reduced rate of disease development after HIV-2 infection as compared to HIV-1","volume":"265","author":"Marlink","year":"1994","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/rmv.1739","article-title":"Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis","volume":"23","author":"Nyamweya","year":"2013","journal-title":"Rev Med Virol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/JVI.70.6.3617-3627.1996","article-title":"Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop","volume":"70","author":"Chen","year":"1996","journal-title":"J Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1128\/JVI.06315-11","article-title":"Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1","volume":"86","author":"Ozkaya Sahin","year":"2012","journal-title":"J Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1128\/JVI.06155-11","article-title":"Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection","volume":"86","author":"Kong","year":"2012","journal-title":"J Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/0471142735.im1211s64","article-title":"Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays","volume":"12","author":"Montefiori","year":"2005","journal-title":"Curr Protoc Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"9195","DOI":"10.1074\/jbc.M114.621185","article-title":"Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate","volume":"290","author":"Sneha Priya","year":"2015","journal-title":"J Biol Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B17","doi-asserted-by":"publisher","first-page":"9069","DOI":"10.1128\/JVI.79.14.9069-9080.2005","article-title":"The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner","volume":"79","author":"Saunders","year":"2005","journal-title":"J Virol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1128\/JVI.06745-11","article-title":"HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes","volume":"86","author":"Doria-Rose","year":"2012","journal-title":"J Virol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature13808","article-title":"Structure and immune recognition of trimeric pre-fusion HIV-1 Env","volume":"514","author":"Pancera","year":"2014","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1128\/JVI.80.3.1414-1426.2006","article-title":"Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants","volume":"80","author":"Li","year":"2006","journal-title":"J Virol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"aac4223","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/COH.0000000000000153","article-title":"HIV broadly neutralizing antibody targets","volume":"10","author":"Wibmer","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"B23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1146\/annurev.immunol.24.021605.090557","article-title":"GP120: target for neutralizing HIV-1 antibodies","volume":"24","author":"Pantophlet","year":"2006","journal-title":"Annu Rev Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/nature13601","article-title":"Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface","volume":"515","author":"Huang","year":"2014","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1128\/JVI.07163-11","article-title":"Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J Virol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7588","DOI":"10.1128\/JVI.00734-12","article-title":"The development of CD4 binding site antibodies during HIV-1 infection","volume":"86","author":"Lynch","year":"2012","journal-title":"J Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1128\/JVI.02789-06","article-title":"Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections","volume":"81","author":"Rodriguez","year":"2007","journal-title":"J Virol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1073\/pnas.1217537110","article-title":"Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9","volume":"110","author":"Julien","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu Rev Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/imr.12073","article-title":"A global approach to HIV-1 vaccine development","volume":"254","author":"Stephenson","year":"2013","journal-title":"Immunol Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1126\/science.1256526","article-title":"A critical question for HIV vaccine development: which antibodies to induce?","volume":"345","author":"Zolla-Pazner","year":"2014","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02841\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:15:19Z","timestamp":1605658519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02841\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,17]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2018.02841"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02841","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,17]]},"article-number":"2841"}}